AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business slows amid a probe ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

Astrazeneca has raised its guidance for the full year despite issues surrounding its presence in China according to today's ...

AstraZeneca, headquartered in Cambridge UK but globally influential, is investing $3.5 billion in the United States to expand ...

The AstraZeneca (LSE:AZN) share price just dipped below £100 per share. The stock has seriously underperformed in recent months, falling from above £130 in August. So, let’s take a look at what’s ...

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...

On the results front, AstraZeneca is among the heavyweight companies in the spotlight. The post-election bounce on Wall ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS is expected to come in at $2.04 in the third quarter, according to a company-compiled consensus ...

The AstraZeneca (LSE: AZN) share price is in freefall at the moment. Yesterday (5 November), it fell 8.4%. Since late August, it has plummeted nearly 25%. So, what’s going on here? And has the share ...

AstraZeneca.com. "AZN Share Price Movement." Bloomberg. “China Detains AstraZeneca Staff in Data, Drug-Import Probes." ...

Learn More. The AstraZeneca (LSE: AZN) share price is in freefall at the moment. Yesterday (5 November), it fell 8.4%. Since late August, it has plummeted nearly 25%. So, what’s going on here?